
Hope S. Rugo, MD, FASCO, gave an overview of ribociclib plus aromatase inhibitor use vs abemaciclib plus aromatase inhibitors for patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Your AI-Trained Oncology Knowledge Connection!


Hope S. Rugo, MD, FASCO, gave an overview of ribociclib plus aromatase inhibitor use vs abemaciclib plus aromatase inhibitors for patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Hope S. Rugo, MD, FASCO, reviewed data from a matching-adjusted indirect comparison study which analyzed quality of life in patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with ribociclib- or abemaciclib-based regimens.

Hope S. Rugo, MD, FASCO, spoke about future analyses of the phase 3 TROPiCS-02 trial that examined sacituzumab govitecan vs physicians’ choice chemotherapy in patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Hope S. Rugo, MD, spoke about results of the phase 3 TROPiCS-02 trial examining sacituzumab govitecan vs physicians’ choice chemotherapy for patients with hormone receptor–positive, HER2-negative advanced breast cancer presented at ASCO 2022.


The breast oncologist from the University of California, San Francisco, discussed new agents being developed in the breast cancer space.

Published: June 9th 2022 | Updated:

Published: April 18th 2022 | Updated:

Published: March 12th 2020 | Updated: